UBS Group
ORMP icon

UBS Group’s Oramed Pharmaceuticals ORMP Stock Holding History

UBS Group’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.7K Buy
11,667
+9,092
+353% +$30.8K ﹤0.01% 7524
2025
Q4 		$7.34K Buy
2,575
+2,218
+621% +$5.72K ﹤0.01% 8456
2025
Q3 		$943 Sell
357
-12,422
-97% -$27.5K ﹤0.01% 9486
2025
Q2 		$28.8K Sell
12,779
-22,804
-64% -$50.3K ﹤0.01% 8195
2025
Q1 		$76.1K Sell
35,583
-77,398
-69% -$179K ﹤0.01% 7255
2024
Q4 		$273K Buy
112,981
+84,797
+301% +$202K ﹤0.01% 6258
2024
Q3 		$68.8K Buy
28,184
+18,893
+203% +$46.1K ﹤0.01% 6614
2024
Q2 		$23.9K Buy
9,291
+4,642
+100% +$11K ﹤0.01% 7190
2024
Q1 		$13.6K Sell
4,649
-417
-8% -$1.17K ﹤0.01% 7094
2023
Q4 		$11.7K Sell
5,066
-1,140
-18% -$2.44K ﹤0.01% 7385
2023
Q3 		$16.2K Buy
6,206
+64
+1% +$202 ﹤0.01% 6913
2023
Q2 		$22K Sell
6,142
-92,992
-94% -$298K ﹤0.01% 6832
2023
Q1 		$216K Buy
99,134
+88,422
+825% +$281K ﹤0.01% 5330
2022
Q4 		$129K Buy
10,712
+2,297
+27% +$17.9K ﹤0.01% 5867
2022
Q3 		$54K Buy
8,415
+3,864
+85% +$31.3K ﹤0.01% 6283
2022
Q2 		$21K Buy
4,551
+1,520
+50% +$8.12K ﹤0.01% 6819
2022
Q1 		$26K Sell
3,031
-10,645
-78% -$109K ﹤0.01% 7151
2021
Q4 		$195K Buy
13,676
+12,502
+1,065% +$261K ﹤0.01% 5725
2021
Q3 		$26K Sell
1,174
-25,507
-96% -$434K ﹤0.01% 6889
2021
Q2 		$357K Buy
26,681
+24,898
+1,396% +$285K ﹤0.01% 4961
2021
Q1 		$18K Buy
1,783
+1,651
+1,251% +$13.6K ﹤0.01% 7469
2020
Q4 		$1K Sell
132
-9,227
-99% -$30K ﹤0.01% 8240
2020
Q3 		$24K Buy
9,359
+5,329
+132% +$18.6K ﹤0.01% 6166
2020
Q2 		$15K Sell
4,030
-3,593
-47% -$12.1K ﹤0.01% 6742
2020
Q1 		$24K Buy
7,623
+7,423
+3,712% +$32.5K ﹤0.01% 6378
2019
Q4 		$1K Sell
200
-1,534
-88% -$5.75K ﹤0.01% 7969
2019
Q3 		$6K Sell
1,734
-189
-10% -$629 ﹤0.01% 7421
2019
Q2 		$7K Buy
1,923
+693
+56% +$2.45K ﹤0.01% 7244
2019
Q1 		$5K Sell
1,230
-1,567
-56% -$5.18K ﹤0.01% 7172
2018
Q4 		$9K Sell
2,797
-396
-12% -$1.64K ﹤0.01% 7287
2018
Q3 		$16K Sell
3,193
-4,973
-61% -$25.8K ﹤0.01% 6931
2018
Q2 		$61K Sell
8,166
-650
-7% -$4.72K ﹤0.01% 5833
2018
Q1 		$57K Sell
8,816
-8,613
-49% -$66.5K ﹤0.01% 5610
2017
Q4 		$157K Buy
17,429
+14,945
+602% +$143K ﹤0.01% 5081
2017
Q3 		$25K Buy
2,484
+2,184
+728% +$18.8K ﹤0.01% 6297
2017
Q2 		$2K Sell
300
-83
-22% -$626 ﹤0.01% 7389
2017
Q1 		$3K Sell
383
-976
-72% -$6.07K ﹤0.01% 7192
2016
Q4 		$8K Sell
1,359
-547
-29% -$3.56K ﹤0.01% 7041
2016
Q3 		$14K Buy
1,906
+1,289
+209% +$10K ﹤0.01% 6560
2016
Q2 		$5K Sell
617
-667
-52% -$5.68K ﹤0.01% 7126
2016
Q1 		$8K Buy
1,284
+667
+108% +$4.47K ﹤0.01% 6791
2015
Q4 		$5K Hold
617
– – ﹤0.01% 7695
2015
Q3 		$3K Sell
617
-2,784
-82% -$17.5K ﹤0.01% 7952
2015
Q2 		$20K Buy
3,401
+710
+26% +$4.86K ﹤0.01% 6870
2015
Q1 		$17K Buy
2,691
+1,174
+77% +$5.67K ﹤0.01% 7147
2014
Q4 		$7K Buy
+1,517
New +$9.98K ﹤0.01% 8711

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group's ORMP Position: Q1 2026 in Review

UBS Group increased its Oramed Pharmaceuticals (ORMP) stake by 353% in Q1 2026, buying an estimated $30.8K and bringing the position to 11,667 shares worth $39.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7524.

UBS Group first reported a position in ORMP in Q4 2014 and has held it in 46 quarters since. The position peaked at $357K in Q2 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • UBS Group held 11,667 shares of Oramed Pharmaceuticals worth $39.7K as of Q1 2026.
  • UBS Group bought 9,092 Oramed Pharmaceuticals shares in Q1 2026, an estimated $30.8K.
  • Oramed Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7524 holding.
  • UBS Group first reported a position in Oramed Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Oramed Pharmaceuticals position peaked at $357K in Q2 2021.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.